玻璃体腔注射阿柏西普与激光光凝对早产儿视网膜病变治疗成功的影响:FIREFLEYE随机临床试验
这项在27个国家64家医院开展的非劣效性3期随机临床试验纳入118例需治疗的早产儿视网膜病变婴儿,按2:1随机接受0.4 mg玻璃体腔注射阿柏西普(n=75)或激光光凝(n=43)。第24周治疗成功率阿柏西普组85.5% vs 激光光凝组82.1%,组间差异3.4%(单侧95%可信区间-8.0%至∞),未达到预设的非劣效界值(下限大于-5%)。
要点
- 阿柏西普组第24周治疗成功率85.5%,激光光凝组82.1%,组间差异3.4%(单侧95%可信区间-8.0%至∞)。
- 因可信区间下限-8.0%未超过预设的-5%界值,阿柏西普未达到非劣效标准。
- 阿柏西普组需要补救治疗的眼占4.8%,激光光凝组占11.1%。
核心结论
- 在早产儿视网膜病变婴儿中,玻璃体腔注射阿柏西普与激光光凝相比,就第24周达到治疗成功的婴儿比例这一主要结局而言,未达到非劣效性标准。
- 作者认为,关于阿柏西普与激光光凝在该人群中的对比效应,需要进一步数据才能得出更明确的结论。
研究设计与样本
- 非劣效性、3期、24周随机临床试验,在亚洲、欧洲和南美洲27个国家64家医院开展。
- 2019年9月25日至2020年8月28日纳入118例婴儿(出生时胎龄≤32周或出生体重≤1500 g),至少1眼为需治疗的早产儿视网膜病变(I区1期+、I区2期+、I区3期、I区3期+、II区2期+或II区3期+)或侵袭性后极部早产儿视网膜病变。
- 婴儿按2:1随机接受0.4 mg玻璃体腔注射阿柏西普(n=75)或激光光凝(n=43)作为基线治疗,允许按预设方案追加治疗。
- 113例接受治疗(平均胎龄26.3周,标准差1.9周;53例(46.9%)为女性;16.8%为侵袭性后极部早产儿视网膜病变,19.5%为I区病变,63.7%为II区病变),104例完成研究。
- 主要结局为开始治疗后24周无活动性早产儿视网膜病变且无不良结构结局的婴儿比例(由研究者评估),需要补救治疗视为治疗失败。
主要发现
- 治疗成功率阿柏西普组85.5% vs 激光光凝组82.1%,组间差异3.4%(单侧95%可信区间-8.0%至∞)。
- 需要补救治疗的眼比例阿柏西普组4.8%(95%CI 1.9%至9.6%)vs 激光光凝组11.1%(95%CI 4.9%至20.7%)。
- 严重不良事件率阿柏西普组眼部13.3%、全身24.0%,激光光凝组眼部7.9%、全身36.8%。
- 3例死亡发生在阿柏西普治疗后4至9周,研究者认为与阿柏西普无关。
关键数值与推荐
- 非劣效界值:治疗差异的单侧95%贝叶斯可信区间下限大于-5%时判定阿柏西普为非劣效。
- 实际结果组间差异3.4%,单侧95%可信区间下限-8.0%,未大于-5%,未达到非劣效标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出,关于阿柏西普与激光光凝在该人群中的对比效应,需要进一步数据才能得出更明确的结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Laser photocoagulation, which is the standard treatment for retinopathy of prematurity (ROP), can have adverse events. Studies of anti-vascular endothelial growth factor injections have suggested efficacy in the treatment of ROP, but few studies have directly compared them with laser treatments. OBJECTIVE: To compare intravitreal aflibercept vs laser photocoagulation in infants with ROP requiring treatment. DESIGN, SETTING, AND PARTICIPANTS: This noninferiority, phase 3, 24-week, randomized clinical trial was conducted in 27 countries (64 hospital sites) throughout Asia, Europe, and South America. Overall, 118 infants (gestational age ≤32 weeks at birth or birth weight ≤1500 g) with ROP severity (zone I stage 1+ [stage 1 plus increased disease activity], zone I stage 2+, zone I stage 3, zone I stage 3+, zone II stage 2+, or zone II stage 3+) requiring treatment or with aggressive posterior ROP in at least 1 eye were enrolled between September 25, 2019, and August 28, 2020 (the last visit occurred on February 12, 2021). INTERVENTIONS: Infants were randomized 2:1 to receive a 0.4-mg dose of intravitreal aflibercept (n = 75) or laser photocoagulation (n = 43) at baseline. Additional treatment was allowed as prespecified. MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of infants without active ROP and unfavorable structural outcomes 24 weeks after starting treatment (assessed by investigators). The requirement for rescue treatment was considered treatment failure. Intravitreal aflibercept was deemed noninferior if the lower limit of the 1-sided 95% bayesian credible interval for the treatment difference was greater than -5%. RESULTS: Among 118 infants randomized, 113 were treated (mean gestational age, 26.3 [SD, 1.9] weeks; 53 [46.9%] were female; 16.8% had aggressive posterior ROP, 19.5% had zone I ROP, and 63.7% had zone II ROP) and 104 completed the study. Treatment (intravitreal aflibercept: n = 75; laser photocoagulation: n = 38) was mostly bilateral (92.9%), and 82.2% of eyes in the intravitreal aflibercept group received 1 injection per eye. Treatment success was 85.5% with intravitreal aflibercept vs 82.1% with laser photocoagulation (between-group difference, 3.4% [1-sided 95% credible interval, -8.0% to ∞]). Rescue treatment was required in 4.8% (95% CI, 1.9% to 9.6%) of eyes in the intravitreal aflibercept group vs 11.1% (95% CI, 4.9% to 20.7%) of eyes in the laser photocoagulation group. The serious adverse event rates were 13.3% (ocular) and 24.0% (systemic) in the intravitreal aflibercept group compared with 7.9% and 36.8%, respectively, in the laser photocoagulation group. Three deaths, which occurred 4 to 9 weeks after intravitreal aflibercept treatment, were considered unrelated to aflibercept by the investigators. CONCLUSIONS AND RELEVANCE: Among infants with ROP, intravitreal aflibercept compared with laser photocoagulation did not meet criteria for noninferiority with respect to the primary outcome of the proportion of infants achieving treatment success at week 24. Further data would be required for more definitive conclusions regarding the comparative effects of intravitreal aflibercept and laser photocoagulation in this population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04004208.
引用
- Stahl A, Sukgen EA, Wu WC, et al. Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial. JAMA. 2022. PMID: 35881122. doi:10.1001/jama.2022.10564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。